文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

电阻抗成像引导的呼气末正压与急性呼吸窘迫综合征患者死亡率:EITVent随机临床试验

Electrical impedance tomography-guided positive end-expiratory pressure and mortality of patients with the acute respiratory distress syndrome: the EITVent randomized clinical trial.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01
一句话结论在中重度ARDS患者中,EIT引导的PEEP设定相比低PEEP/FiO2表策略未显著降低28天死亡率(HR 0.96,95%CI 0.65-1.41)。

这项多中心随机试验纳入190例中重度ARDS成人患者,比较电阻抗成像(EIT)引导的PEEP设定(递减PEEP试验中塌陷-过度膨胀交叉点值)与经典低PEEP/FiO2表策略。主要终点28天死亡率在EIT组为55.9%(52例),低PEEP/FiO2表组为52.6%(51例),HR 0.96(95%CI 0.65-1.41),P=.821。无呼吸机天数及其他次要临床和安全结局均无差异。试验因无效性提前终止,可能把握度不足。在肺复张性较高的患者中,EIT引导PEEP组死亡率较低(35.6% vs 60.0%,HR 0.49,95%CI 0.26-0.91,P=.024)。

要点

  • 在中重度ARDS成人患者中,EIT引导PEEP相比低PEEP/FiO2表策略未显著降低28天死亡率:EIT组55.9% vs 低PEEP/FiO2表组52.6%,HR 0.96(95%CI 0.65-1.41),P=.821。
  • 前7天两组PEEP水平无差异(边际均值差0.2,SE 0.1,P=.187)。
  • 无呼吸机天数及其他次要临床和安全结局在两组间均无差异。
  • 在肺复张性较高的患者中(采用复张-膨胀比方法评估),EIT引导PEEP组死亡率较低:16/45(35.6%) vs 27/45(60.0%),HR 0.49(95%CI 0.26-0.91),P=.024。
  • 试验因无效性提前终止,基于预定的中期分析,可能把握度不足。

适用人群与场景

  • 成人中重度急性呼吸窘迫综合征(ARDS)患者,来自中国五个中心,纳入时间2022年2月至2023年6月。

处置流程与药物剂量

  • EIT引导PEEP组:通过递减PEEP试验,取塌陷-过度膨胀交叉点值设定PEEP。
  • 对照组:采用经典低PEEP/FiO2表策略设定PEEP。

研究设计与关键结果

  • 随机临床试验,纳入190例中重度ARDS成人患者,来自中国五个中心,2022年2月至2023年6月。
  • 主要终点28天死亡率:EIT引导PEEP组55.9%(52例) vs 低PEEP/FiO2表组52.6%(51例),HR 0.96(95%CI 0.65-1.41),P=.821。
  • 前7天PEEP水平组间无差异(边际均值差0.2,SE 0.1,P=.187)。
  • 无呼吸机天数及其他次要临床和安全结局均无差异。
  • 肺复张性较高患者中,EIT引导PEEP组死亡率16/45(35.6%) vs 低PEEP/FiO2表组27/45(60.0%),HR 0.49(95%CI 0.26-0.91),P=.024。
  • 试验因无效性提前终止,基于预定的中期分析。

证据类型、等级与局限

  • 证据类型:随机临床试验(RCT)。
  • 局限:试验因无效性提前终止,研究可能把握度不足,无法检测出有临床意义的差异。

对床旁实践的改变

  • 在中重度ARDS成人患者中,EIT引导PEEP设定相比低PEEP/FiO2表策略未显著降低28天死亡率,不能常规替代低PEEP/FiO2表策略。
  • 对于肺复张性较高的患者(采用复张-膨胀比方法评估),EIT引导PEEP可能降低死亡率(HR 0.49,95%CI 0.26-0.91),但该结果为次要分析。
  • 试验因无效性提前终止,可能把握度不足,阳性结果需谨慎解读。

指南或共识出处

  • 临床试验注册号:clinicaltrials.gov NCT05207202。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: Physiological studies showed benefits for bedside setting of personalized positive end-expiratory pressure (PEEP) by electrical impedance tomography (EIT), balancing lung overdistension and collapse.

OBJECTIVES: To evaluate whether EIT-guided PEEP improves the clinical outcomes of patients with acute respiratory distress syndrome (ARDS) compared to the lower PEEP/FiO2 table strategy.

METHODS: This randomized trial enrolled adult patients with moderate to severe ARDS across five sites in China from February 2022 to June 2023. Participants were randomly assigned to EIT-guided PEEP (collapse-overdistension crossing point value by decremental PEEP trial) or the classical lower PEEP/FiO2 table. The primary outcome was 28-day mortality.

MEASUREMENTS AND MAIN RESULTS: The trial was terminated early for futility, based on a pre-planned interim analysis. A total of 190 patients were included and completed follow-up. PEEP levels didn't differ between groups during the first 7 days (difference in marginal means 0.2 [SE 0.1]; P = .187). At 28 days, mortality was 52 patients (55.9%) in the EIT-guided PEEP group and 51 patients (52.6%) in the lower PEEP/FiO2 table group (hazard ratio [HR] 0.96 [95% CI, 0.65-1.41]; P = .821). Ventilator-free days and other secondary clinical and safety outcomes did not differ, either. However, EIT-guided PEEP assigned higher PEEP and decreased mortality in patients with higher lung recruitability, as assessed by the recruitment-inflation ratio method (16 [35.6%] of 45 patients vs 27 [60.0%] of 45 patients; HR 0.49 [95% CI, 0.26-0.91]; P = .024).

CONCLUSIONS: In patients with moderate to severe ARDS, EIT-guided PEEP did not significantly reduce 28-day mortality compared with the lower PEEP/FiO2 table strategy. Due to early termination, the study may have been underpowered to detect a clinically important difference.

TRIAL REGISTRATION: clinicaltrials.gov NCT05207202.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Yuan X, Zhong M, Li Z, et al. Electrical impedance tomography-guided positive end-expiratory pressure and mortality of patients with the acute respiratory distress syndrome: the EITVent randomized clinical trial. Am J Respir Crit Care Med. 2026. PMID: 41738148. doi:10.1093/ajrccm/aamaf125

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。